Lane Scott D, Green Charles E, Schmitz Joy M, Rathnayaka Nuvan, Fang Wendy B, Ferré Sergi, Moeller F Gerard
Center for Neurobehavioral Research on Addictions, Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center - Houston, Houston, TX USA.
Center for Human Toxicology, University of Utah, Salt Lake City, UT, USA.
J Addict Res Ther. 2014;5(2):176. doi: 10.4172/2155-6105.1000176.
Due to indirect modulation of dopamine transmission, adenosine receptor antagonists may be useful in either treating cocaine use or improving disrupted cognitive-behavioral functions associated with chronic cocaine use. To compare and contrast the stimulant effects of adenosine antagonism to direct dopamine stimulation, we administered 150 mg and 300 mg caffeine, 20 mg amphetamine, and placebo to cocaine-dependent vs. healthy control subjects, matched on moderate caffeine use. Data were obtained on measures of cardiovascular effects, subjective drug effects (ARCI, VAS, DEQ), and a probabilistic reward-learning task sensitive to dopamine modulation. Levels of salivary caffeine and the primary caffeine metabolite paraxanthine were obtained on placebo and caffeine dosing days. Cardiovascular results revealed main effects of dose for diastolic blood pressure and heart rate; follow up tests showed that controls were most sensitive to 300 mg caffeine and 20 mg amphetamine; cocaine-dependent subjects were sensitive only to 300 mg caffeine. Subjective effects results revealed dose × time and dose × group interactions on the ARCI A, ARCI LSD, and VAS 'elated' scales; follow up tests did not show systematic differences between groups with regard to caffeine or d-amphetamine. Large between-group differences in salivary paraxanthine (but not salivary caffeine) levels were obtained under both caffeine doses. The cocaine-dependent group expressed significantly higher paraxanthine levels than controls under 150 mg and 3-4 fold greater levels under 300 mg at 90 min and 150 min post caffeine dose. However, these differences also covaried with cigarette smoking status (not balanced between groups), and nicotine smoking is known to alter caffeine/paraxanthine metabolism via cytochrome P450 enzymes. These preliminary data raise the possibility that adenosine antagonists may affect cocaine-dependent and non-dependent subjects differently. In conjunction with previous preclinical and human studies, the data suggest that adenosine modulating drugs may have value in the treatment of stimulant use disorders.
由于对多巴胺传递的间接调节作用,腺苷受体拮抗剂可能在治疗可卡因使用或改善与长期使用可卡因相关的认知行为功能紊乱方面有用。为了比较和对比腺苷拮抗作用与直接多巴胺刺激的兴奋作用,我们对可卡因依赖者和健康对照者给予150毫克和300毫克咖啡因、20毫克苯丙胺及安慰剂,这些受试者的咖啡因使用量适度且相互匹配。获取了心血管效应、主观药物效应(ARCI、VAS、DEQ)以及对多巴胺调节敏感的概率性奖励学习任务的测量数据。在服用安慰剂和咖啡因的日子里获取唾液中咖啡因及主要咖啡因代谢物副黄嘌呤的水平。心血管结果显示舒张压和心率存在剂量主效应;后续测试表明,对照组对300毫克咖啡因和20毫克苯丙胺最为敏感;可卡因依赖者仅对300毫克咖啡因敏感。主观效应结果显示在ARCI A、ARCI LSD和VAS“兴奋”量表上存在剂量×时间和剂量×组间交互作用;后续测试未显示两组在咖啡因或右旋苯丙胺方面存在系统性差异。在两种咖啡因剂量下,唾液副黄嘌呤(而非唾液咖啡因)水平在组间存在较大差异。在咖啡因给药后90分钟和150分钟,可卡因依赖组在150毫克剂量下的副黄嘌呤水平显著高于对照组,在300毫克剂量下则高出3至4倍。然而,这些差异也与吸烟状况相关(两组间不均衡),且已知尼古丁吸烟会通过细胞色素P450酶改变咖啡因/副黄嘌呤代谢。这些初步数据提出了腺苷拮抗剂可能对可卡因依赖者和非依赖者产生不同影响的可能性。结合先前的临床前和人体研究,这些数据表明腺苷调节药物可能在治疗兴奋剂使用障碍方面具有价值。